⚠️ Teaching Case Note: This case has been de-identified and reconstructed for educational purposes. Clinical details reflect real surgical decision-making and outcomes. Patient identity is fully protected.
Opening a Blocked Artery That Couldn't Be Reached From the Front
He had lived with chest pain for three years. A 62-year-old man with hypertension, diabetes, and three decades of smoking — two years earlier, a heart attack had already claimed part of his LAD artery, treated with a drug-eluting stent. Now the pain had returned at rest. His exercise tolerance had collapsed to NYHA Class III. His ejection fraction had fallen to 45%.
Coronary angiography identified the culprit: a chronic total occlusion (CTO) of the left circumflex artery (LCX), 25 mm long, heavily calcified, with no visible stump — a J-CTO score of 3, placing it in the highest difficulty category. The standard approach — advancing a guidewire forward through the blockage — carried a high probability of failure. The territory supplied by the LCX contained viable myocardium. Without revascularization, further functional decline was inevitable.
Dr. Junbo Ge's team at Zhongshan Hospital, Fudan University, chose the retrograde approach.
The Diagnosis: High-Complexity CTO With Viable Myocardium at Risk
The angiographic picture was detailed. The LAD stent from two years prior remained patent at the proximal segment, with diffuse mid-vessel disease at 70% stenosis. The LCX showed chronic total occlusion at the mid-segment — 25 mm of blocked artery, calcified throughout, with no residual stump to guide wire entry. The right coronary artery (RCA) was dominant with 50% distal stenosis. Resting ECG showed ST depression in leads V4–V6. Echocardiography confirmed LVEF 45% with anterior wall hypokinesis.
The key finding that shaped the treatment decision: the LCX territory contained viable but ischemic myocardium. Revascularization offered the prospect of functional recovery — not just symptom relief. The risk of leaving it untreated was progressive heart failure.
Pre-procedural coronary CT angiography (CCTA) was performed to map the septal collateral channels connecting the RCA to the distal LCX — the anatomical route that would make retrograde access possible. The collateral anatomy was favorable. The team planned accordingly.
The Procedure: Retrograde Wire Crossing in Four Phases
CTO percutaneous coronary intervention (PCI) via the retrograde approach is among the most technically demanding procedures in interventional cardiology. It requires navigating a guidewire backward through collateral vessels — vessels not designed for wire passage — to approach the occlusion from the distal end, where the anatomy is often more favorable for crossing.
Phase 1 — Antegrade protection. A guidewire was advanced through the LAD to a distal branch, establishing a protected channel and maintaining collateral flow to the LCX territory throughout the procedure. This dual-wire protection strategy reduces the risk of ischemic complications during the extended procedural time that retrograde CTO work requires.
Phase 2 — Retrograde access via septal collaterals. Using the CCTA roadmap, a Sion Blue guidewire (Asahi Intecc) — selected for its atraumatic tip and high trackability through tortuous collateral channels — was advanced retrogradely through the RCA septal branches toward the distal LCX. A Corsair microcatheter (Asahi Intecc) provided coaxial support, enabling the wire to navigate the collateral anatomy without vessel injury. Retrograde access to the distal LCX was established in under 15 minutes — a direct result of the pre-procedural CCTA planning.
Phase 3 — Wire externalization and track formation. With the retrograde wire positioned distal to the occlusion, a Gaia Third guidewire (Asahi Intecc) — chosen for its penetration force and torque response — was advanced antegradely to meet the retrograde wire within the occlusion. The two wires were connected to form a continuous guidewire track through the blocked segment: the "wire rail" that would guide all subsequent equipment.
Phase 4 — Balloon dilatation and stent implantation. Sequential balloon pre-dilatation prepared the calcified occlusion for stent delivery. Two drug-eluting stents (Xience Sierra, Abbott Vascular) were deployed to cover the full occlusion length and adjacent disease. Post-dilatation with a non-compliant balloon (NC Quantum, Boston Scientific) optimized stent apposition — critical in a calcified lesion where incomplete expansion increases restenosis and thrombosis risk. Final angiography confirmed TIMI 3 flow with less than 5% residual stenosis.
Throughout the procedure, activated clotting time (ACT) was monitored continuously to maintain therapeutic anticoagulation. Total procedural time was consistent with published retrograde CTO benchmarks for J-CTO score 3 lesions.
Outcomes: Ejection Fraction Recovered, Symptoms Resolved
The functional results were rapid and substantial. At one month post-procedure, LVEF had recovered from 45% to 52% — a 7-point improvement reflecting the restoration of blood supply to previously ischemic but viable myocardium. Chest pain had resolved completely. NYHA functional class improved from III to I.
At six-month angiographic follow-up, both stents remained fully patent with no in-stent restenosis or thrombosis. Dual antiplatelet therapy — aspirin plus ticagrelor, extended to 12 months given the patient's diabetic status and high thrombotic risk — was well tolerated throughout.
His own words: "Three years of chest pain, and then it was gone. I didn't believe it at first. The doctors explained every step before they did it — what the wire would do, why they were going in from the other direction. Understanding what was happening made it easier to trust the process."
Why the Retrograde Approach — and Why It Requires Specialist Expertise
For CTO lesions with J-CTO scores of 3 or above — the highest complexity tier — the antegrade-only success rate in experienced hands is 50–60%. The retrograde approach, in centers with dedicated CTO programs, achieves 85–90% success for the same lesion complexity. The difference is not incremental; it is the difference between revascularization and medical management alone for patients who have failed or are unlikely to succeed with standard techniques.
The retrograde approach requires specific infrastructure: CCTA for pre-procedural collateral mapping, a library of specialized guidewires and microcatheters, a team trained in dual-access technique, and the procedural volume to maintain proficiency. It is not available at every cardiac catheterization laboratory. At Zhongshan Hospital, it is routine.
The antiplatelet strategy in this case also reflects individualized risk assessment. Ticagrelor was selected over clopidogrel based on the PLATO trial subgroup data showing superior stent thrombosis reduction in diabetic patients — a population at disproportionately high restenosis risk after complex PCI.
Expert Commentary — Dr. Junbo Ge
"Chronic total occlusions represent the final frontier of coronary intervention. For years, they were considered untreatable by PCI — patients were referred for bypass surgery or managed medically. The development of retrograde techniques, specialized wire systems, and structured training programs has changed that calculus fundamentally.
This case illustrates three principles that define successful CTO intervention. First, pre-procedural planning is not optional — CCTA collateral mapping reduced our retrograde access time to under 15 minutes in a J-CTO 3 lesion. Second, wire selection is a clinical decision, not a preference — the combination of Sion Blue for collateral navigation and Gaia Third for antegrade penetration reflects specific biomechanical requirements at each phase. Third, the procedure does not end at TIMI 3 flow — stent optimization with non-compliant balloon post-dilatation and individualized antiplatelet selection are what determine the six-month angiogram.
The patient's ejection fraction recovered 7 points in one month. That is viable myocardium that was waiting for blood supply. Finding it, and restoring it, is what complex coronary intervention is for."
About Dr. Junbo Ge
Dr. Junbo Ge is Director of the Department of Cardiology at Zhongshan Hospital, Fudan University, and one of China's most prominent interventional cardiologists. He specializes in complex coronary interventions, structural heart disease, and cardiac imaging. Dr. Ge has performed thousands of high-risk PCI procedures and is a leading voice in cardiovascular innovation in Asia, with particular expertise in CTO intervention, bifurcation lesions, and left main coronary artery disease.
How CMCS Supported This Patient
China Medical Concierge – Shanghai (CMCS) coordinated the full care pathway: case review and specialist matching at Zhongshan Hospital Fudan University, pre-procedural CCTA logistics and cardiology consultation scheduling, on-site Mandarin-English interpretation for all consultations and procedural consent discussions — including the detailed informed consent process for a high-complexity retrograde CTO intervention — family communication support during the catheterization laboratory procedure, and post-procedural follow-up coordination including six-month angiographic review scheduling, antiplatelet therapy management, and cardiac rehabilitation referral.
For international patients and expatriates in Shanghai facing complex coronary artery disease — including CTO lesions, multivessel disease, or prior failed interventions — CMCS provides end-to-end support from first cardiology consultation to long-term follow-up.
📧 contract@medicalsh.com | 📱 WhatsApp | 🌐 medicalsh.com
0 comentarios